Jaguar Health, Inc. Stock price

Equities

JAGX

US47010C7065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0899 USD +23.32% Intraday chart for Jaguar Health, Inc. +12.52% -40.62%
Sales 2021 4.34M Sales 2022 11.96M Capitalization 13.15M
Net income 2021 -52M Net income 2022 -47M EV / Sales 2021 13.9 x
Net Debt 2021 12.31M Net Debt 2022 29.37M EV / Sales 2022 3.56 x
P/E ratio 2021
-0.88 x
P/E ratio 2022
-0.18 x
Employees 60
Yield 2021 *
-
Yield 2022
-
Free-Float 97.89%
More Fundamentals * Assessed data
Dynamic Chart
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs CI
Top Premarket Gainers MT
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs CI
Jaguar Health, Inc. announced that it has received $0.06 million in funding CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall MT
Transcript : Jaguar Health, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Jaguar Health, Inc. - Special Call
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance MT
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome CI
Jaguar Health, Inc. announced that it expects to receive $0.06 million in funding CI
More news
1 day+7.00%
1 week-2.78%
Current month+30.17%
1 month+33.10%
3 months-52.56%
6 months-70.91%
Current year-49.27%
More quotes
1 week
0.07
Extreme 0.0653
0.08
1 month
0.06
Extreme 0.058
0.16
Current year
0.05
Extreme 0.0512
0.16
1 year
0.05
Extreme 0.0512
1.22
3 years
0.05
Extreme 0.0512
513.00
5 years
0.05
Extreme 0.0512
5 512.52
10 years
0.05
Extreme 0.0512
148 365.15
More quotes
Managers TitleAgeSince
Founder 65 13-06-05
Director of Finance/CFO 60 19-04-30
Chief Tech/Sci/R&D Officer 60 17-04-30
Members of the board TitleAgeSince
Founder 65 13-06-05
Chairman 80 14-01-31
Director/Board Member 71 16-03-31
More insiders
Date Price Change Volume
24-03-28 0.0899 +23.32% 60 481 328
24-03-27 0.0729 +5.65% 30,559,549
24-03-26 0.069 -4.43% 42,135,244
24-03-25 0.0722 +0.42% 34,089,117
24-03-22 0.0719 -8.99% 57,459,509

Delayed Quote Nasdaq, March 28, 2024 at 11:20 am EDT

More quotes
Jaguar Health, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. It operates through two segments: human health and animal health. Human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. Its subsidiary includes Napo Pharmaceuticals, Inc., which focuses on developing and commercializing plant-based human pharmaceuticals.
More about the company
  1. Stock
  2. Equities
  3. Stock Jaguar Health, Inc. - Nasdaq